Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-03-22
2011-03-22
Wilson, James O (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S354000
Reexamination Certificate
active
07910587
ABSTRACT:
The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof:which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
REFERENCES:
patent: 6329379 (2001-12-01), Llinas-Brunet et al.
patent: 6608027 (2003-08-01), Tsantrizos et al.
patent: 6995174 (2006-02-01), Wang et al.
patent: 7173004 (2007-02-01), McPhee et al.
patent: 7176208 (2007-02-01), Nakajima et al.
patent: 7186747 (2007-03-01), Arasappan et al.
patent: 7635683 (2009-12-01), Gai et al.
patent: 2002/0037998 (2002-03-01), Llinas-Brunet et al.
patent: 2005/0137139 (2005-06-01), Perni et al.
patent: 2005/0261200 (2005-11-01), Miao et al.
patent: 2006/0172950 (2006-08-01), Wang et al.
patent: 2007/0078081 (2007-04-01), Casarez et al.
Rancourt et. al. “Peptide Based Inhibitors of the Hepatitis C Virus NS3 Protease: Structure-Activity Relationship at the C-Terminal Position,” J. Med. Chem. 2004, 47, 2511-2522.
Wangsell F., Design and Synthesis of Serine and Aspartic Protease Inhibitors, Linkopig Studies and Technology, Thesis No. 1264.
Llinas-Brunet, et. al., Biooganic & Medicinal Chemistry Letters, 8, 1998, 1713-1718.
Gai Yonghua
Or Yat Sun
Wang Zhe
Elmore Patent Law Group P.C.
Elmore, Esq. Carolyn S.
Enanta Pharmaceuticals, Inc.
Harlan Edgar W.
Sackey Ebenezer
LandOfFree
Quinoxalinyl dipeptide hepatitis C virus inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Quinoxalinyl dipeptide hepatitis C virus inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Quinoxalinyl dipeptide hepatitis C virus inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2666240